International AIDS Society - Workshop · International AIDS Society - Workshop ... line u2. 8...

International AIDS Society - Workshop”Towards a Cure”: HIV Reservoirs and Strategies to Control Them16 & 17 July 2010, University of Vienna

PROGRAMME

InternatIonal aIDS SocIety WorkShop

With generous support from:

Organized by:

International AIDS Society71 avenue louis casai

1216 cointrinGeneva, Switzerland

tel: +41 22 710 08 00Fax: +41 22 710 08 99

email: [email protected]

3

Table of ContentWelcome Statement ...................................................................................................................4

IntroDuctIon ...............................................................................................................................6

16 July 2010 ....................................................................................................................................8

opening Session - the clinical Implications of hIV persistence during therapy ..............................8

Where and What are Viral reservoirs? hIV-1 reservoirs and Sanctuary Sites ..............................................................................................8

What are the mechanisms of persistence? ......................................................................................10

17 July 2010 ..................................................................................................................................12

What is the role of the Immune System in hIV persistence? .........................................................12

What host Factors are at play? .......................................................................................................14

What are potential therapeutic Interventions and how to evaluate them? ...................................16

closing Session - eradication versus remission: Is eradication possible? ....................................18

poSter exhIbItIon ....................................................................................................................19

hIV reSerVoIrS roaDmap at aIDS 2010 ................................................................................27


Welcome StatementDear colleagues,

on behalf of the International aIDS Society (IaS), it is my pleasure to welcome you to the workshop: “towards a cure”: hIV reservoirs and Strategies to control them.

attending this pre-conference workshop are senior, mid-career and junior scientists, as well as a number of clinical researchers and community representatives. also in attendance are journalists from renowned scientific journals and senior administrators from major research institutions around the world. this workshop places strong emphasis on ensuring representation of scientific excel-lence throughout the world with scholarships being provided for more than 65 participants.

the workshop is closely linked to the xVIII International aIDS Conference (AIDS 2010). Sixty-five basic science and clinical science abstracts submitted to the xVIII International aIDS conference and which are related to the topic of viral reservoirs and strategies to control them will be presented and discussed here, and results will be shared with the expected 20,000-25,000 participants attending aIDS 2010 through a plenary session, abs-tract presentations, a professional development workshop for advanced researchers, as well as at a press conference.

In order to reinforce the impact of this workshop, the issues and findings will be disseminated through the publication of the works-hop’s abstracts in the Journal of the International aIDS Society (JIaS) along with an impact report.

We look forward to a productive few days of meetings and conversation.

Sincerely,

Françoise barré-SinoussiIaS upcoming president-elect

4

WE

. CO

nn

EC

T.W

E. P

RO

MO

TE. W

E. M

Ob

IlIz

E

5

International Steering committee members programme committee members

- Françoise barré-Sinoussi, France - ben berkhout, the netherlands - emily blitz, Switzerland - myron cohen, united States - aikichi Iwamoto, Japan - pontiano kaleebu, uganda - Julio montaner, canada - paula munderi, uganda - anton pozniak, united kingdom - manuel romaris, belgium - christine rouzioux, France - alexandra trkola, Switzerland - mark Wainberg, canada - Jack Whitescarver, united States

- Françoise barré-Sinoussi, France - monsef benkirane, France - emily blitz, Switzerland - nicolas chomont, united States - tae-Wook chun, united States - David Goldstein, united States - paul Gorry, australia - Shirin heidari, Switzerland - alain lafeuillade, France - Javier martinez-picado, Spain - paula munderi, uganda - nicaise ndembi, uganda - anton pozniak, united kingdom - christine rouzioux, France - alexandra trkola, Switzerland - Didier trono, Switzerland - carine Van lint, belgium - eric Verdin, united States

Opening and Closing Sessions:

these sessions feature keynote addresses delivered by some of the world’s most distinguished researchers. the sessions will take place in the Grosser Festsaal.

Mixed Sessions: Overview and Abstracts

most sessions of the workshop include an invited overview pre-sentation by renowned scien-tists and three to five oral abs-tract presentations. the highest scoring abstracts were ultima-tely selected for the workshop programme by the programme committee. the abstract driven component of the pre-conference workshop offers the highest cali-ber of state-of-the-art knowledge and peer-reviewed research. these sessions will also take place in the Grosser Festsaal.

Poster Viewing Sessions

the poster exhibition has been generated from peer-reviewed abstracts and covers a wide variety of topics organized by category, matching the session’s themes. posters will be displayed for viewing in the Senatsaal room from 12:30 on 16 July to 18:30 on 17 July 2010. poster exhibitors have been requested to stand by

their posters between 12:30 and 14:00 on both days to answer questions. the list of poster exhi-bition abstracts is available at the end of this programme.

Abstracts Embargo Policy

most abstracts presented at the workshop will also be pre-sented at the xVIII International aIDS conference. the content of the abstracts, marked “under embargo until xx-xx” should not be published or communicated to a third party before their pre-sentation at the conference. If you have any doubt on whether you can publish the content of an abstract, please contact the organizers.

Rapporteurs

Alberto bosque, university of utah, uSAndrea Savarino, Istituto Superiore de Sanità, ItalyAsier Sáez-Cirión, Institut pasteur, FranceJosé Alcami, Instituto de Salud carlos III, SpainMichael Roche, burnet Institute, australiaXavier Contreras, Institut de Génétique humaine, France

Report Coordinator

Richard Jefferys, treatment action Group

Introduction


6

7

VenueUniversity of ViennaDr.-karl-lueger-ring 1 - a-1010 Wienmetro Schottentor-universitat, line u2

8

14:00-14:30Opening Session The Clinical Implications of HIV Persistence during Therapy co-chairs – Françoise barré-Sinoussi, France and Jack Whitescarver, uS

this keynote address will focus on the clinical implications of hIV persistence: ongoing inflamma-tion, t-cell turnover/dysfunction, lack of immune reconstitution, vascular dysfunction, and non-aIDS morbidities.

Keynote SpeakerSteven G. Deeks is a professor of medicine in residence at the university of california, San Francisco and a faculty member in the positive health program at San Francisco General hospital. he is a recognized expert of the immunopathogenesis of hIV, and works from a clinical pers-pective on identifying how the virus and host interact to cause disease, and how to translate information learned from such studies into the clinic.

14:30-16:15 Where and What are Viral Reservoirs? HIV-1 Reservoirs and Sanctuary Sites co-chairs – maureen Goodenow, uS and paul Gorry, australia

long-lived reservoirs of hIV-1 are a barrier to effective anti-retroviral therapy, and an obstacle for strategies aimed at eradicating hIV-1 from the body. persistent reservoirs may include latently infected cells or sanctuary sites where anti-retroviral drug penetrance is compromised. moreover, the cell type and mechanism of viral latency may be influenced by anatomical location. this ses-sion will provide a cutting edge perspective of hIV-1 reservoirs and viral sanctuary sites that subvert viral eradication strate-gies, and will provide a frame-work for subsequent sessions in this workshop.

16 July 2010

Satya Dandekar

Steven G. Deeks


9

HIV Reservoirs and Mucosal Immune Restoration During HAARTOverview Speaker Satya Dandekar is professor of microbiology and chairperson of the Department of medical microbiology and Immunology at the university of california, Davis. her research program is focused on hIV and simian immunodeficiency virus (SIV) pathogenesis with specific emphasis on mucosal immunol-ogy and viral pathogenesis.

Abstracts S1.1. CD4+ T-cell reconstitu-tion, T-cell activation, and memory T-cell subset com-position in blood and gut of HIV- and ART-suppressed HIV+ patients: implications for HIV persistence in the gut, S. Yukl1,2, E. Sinclair2,3, L. Epling2,3, Q. Li4, A. Shergill1,2, K. McQuaid1,2, L. Duan4, B. Hare2,3, H. Lampiris1,2, A. Haase4, D. Havlir2,3, J. Wong1,2, PLUS Study Group 1San Francisco VA Medical Center, San Francisco, United States, 2University of California San Francisco (UCSF), San Francisco, United States, 3San Francisco General Hospital, San Francisco, United States, 4University of Minnesota, Minneapolis, United States. under embargo until 22 July 2010.

S1.2. Residual HIV replication in the gut of aviremic treated individuals correlates with persistent immune activation and increased plasma levels of lPSG. d’Ettorre1, M. Andreotti2, M. Paiardini3, L. Zaffiri4, G. Ceccarelli4, M.C. Rizza4, S. Vella2, C.M. Mastroianni5, G. Silvestri3, V. Vullo4, 1University of Rome Sapienza, Tropical and Infectious Diseases, Rome, Italy, 2ISS, Department of Drugs, Rome, Italy, 3University of Pennsylvania, Department of Pathology and Laboratory Medicine, Philadelphia, United States, 4’Sapienza’ University, Department of Tropical and Infectious Diseases, Roma, Italy, 5’Sapienza’ University - Polo Pontino, Department of Infectious Diseases, Latina, Italy. under embargo until 22 July 2010.

S1.3. Most HIV DnA in PbMC is present in non-gut homing, resting memory CD4 T-cell with a ß7-CD38-CD127high phenotype, K.K. Koelsch1,2, Y. Xu1,2, M. Bailey1,2, K. McBride1,2, N. Seddiki1,2, K. Suzuki2, J. Murray3, D.A. Cooper1,2, A.D. Kelleher1,2, J. Zaunders2, 1University of New South Wales / NCHECR, Darlinghurst, Australia, 2St Vincents Centre for Applied Medical Research, Darlinghurst,

Australia, 3University of New South Wales, NCHECR / Dept. of Mathmatics, Kensington, Australia. under embargo until 22 July 2010.

S1.4. Astrocytes are a signifi-cant CnS reservoir of provi-ral HIV-1 DnA and contribute to the pathogenesis of HIV-associated dementia, M. Churchill1,2, P.R. Gorry1,2,3, D. Cowley1, L. Gray1, C. Pardo4, J. McArthur4, B.J. Brew5, S.L. Wesselingh1,2, 1Burnet Institute, Centre for Virology, Melbourne, Australia, 2Monash University, Department of Medicine, Melbourne, Australia, 3University of Melbourne, Department of Microbiology and Immunology, Melbourne, Australia, 4Johns Hopkins University School of Medicine, Department of Neurology, Baltimore, United States, 5St. Vincent’s Hospital, Department of Neurology and St. Vincent’s Centre for Applied Medical Research, Darlinghurst, Australia. under embargo until 20 July 2010.

S1.5. Where are macrophage-tropic viruses?, G. Schnell1, S. Joseph1, S. Spudich2, R. Price2, R. Swanstrom1, 1UNC Center For AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, USA;

2Department of Neurology, University of California at San Francisco, San Francisco, USA.

10


16:30-18:15 What are the Mechanisms of Persistence?co-chairs – mario Stevenson, uS and monsef benkirane, France

both cellular and anatomical reservoirs have been identified in patients under highly active antiretroviral therapy (haart). the persistence of these hIV reservoirs seriously challeng-es the hope of complete viral eradication by haart. to better tackle the problem of virus reac-tivation and subsequent eradi-cation by haart, many labo-ratories around the world have focused on understanding the molecular mechanisms involved in the establishment and main-tenance of hIV-1 latency and in the transcriptional reactiva-tion from latency as well as on identification of the anatomical reservoirs. this session will give an update on basic research, to discuss how these findings can be translated into potential thera-peutic strategies and to explore new ideas for the future.

Overview Speaker Eric Verdin is Senior Investi-gator at the Gladstone Institute of Virology and Immunology and professor of medicine at the university of california, San Francisco. his research focuses on the mechanism of hIV transcription by identifying immune modulators that inhibit hIV transcription and on the mechanism of hIV latency, as well as the role of the chromatin environment on transcriptional regulation and, in particular, the biology of histone deacetylases.

11

Abstracts S2.1. novel pathways of tran-scriptional and post-tran-scriptional regulation of post-integrative HIV-1 latency, A. Marcello, A. Kula, M. Dieudonne, A. Knezevich, P. Maiuri, ICGEB, Trieste, Italy under embargo until 22 July 2010.

S2.2. The cellular cofactor CTIP2 is a key regulator of HIV-1 latency, T. Cherrier1, C. Marban1,2, C. Schwartz1, L. Redel1, C. Van Lint3, O. Rohr1, 1University of Strasbourg / INSERM, Strasbourg, France, 2University of California, Los Angeles, United States, 3Université Libre de Bruxelles, IBMM, Gosselies, Belgium, under embargo until 20 July 2010.

S2.3. HIV-1 Tat complexes reveal subunit composition of active P-TEFb and stable association with 7SKsnRnP,B. Sobhian1, N. Laguette1, A. Yatim2, M. Nakamura1, Y. Levy2, R. Kiernan1, M. Benkirane1, 1Institute of Human Genetic, CNRS-UPR1142, Montpellier, France, 2Institut Mondor, INSERM U955, Créteil, France, under embargo until 22 July 2010.

Mechanisms of HIV Persistence in Infected Individuals Receiving Antiretroviral TherapySpeaker - Tae-Wook Chun received his ph.D. degree at the Johns hopkins university School of medicine in 1997. While working with robert Siliciano at Johns hopkins, he identified and character-ized latently infected, resting cD4+ t-cell in hIV-infected individuals. he conducted his postdoctoral work in anthony Fauci’s laboratory at the national Institute of allergy and Infectious Diseases. he is cur-rently an associate Scientist at nIh and continues to study the role of viral reservoirs in the pathogenesis of hIV in infected individuals receiving effective antiretroviral therapy.

Debate on Abstract Poster # 15: A three years follow-up of long term con-trol of HIV-1 after alloge-neic CCR5-delta32 stem cell transplantation

Participants: Eric Verdin, Gero Hütter, Mario Stevenson, Mark Wainberg, Monsef Benkirane, Tae-Wook Chun,

18:30 - Reception offered by the Federal Ministry of Science and Research of the Republic of Austria at the Academy of Sciences aula der Wissenschaften, Wollzeile 27a, a-1010 Vienna you will be escorted to the venue.

presentation of the IaS-anrS young Investigator prize on hIV reservoirs by Françoise barré-Sinoussi, Governing council member of the IaS and Jean-François Delfraissy, Director of the agence nationale de recherche sur le SIDa et les hépatites Virales (anrS).

the prize will be awarded to patricia monteiro (université de montréal, microbiologie et Immunologie, chum-research center, Saint-luc hospital, the French national Institute of health and medical research unit 743, montreal, canada) for the abstract # 24, Peripheral blood CCR4+ CCR6+ and CXCR3+ CCR6+ CD4+ T-cells are highly permissive to HIV-1 infection.Tae-Wook Chun

12

8:30-10:15 What is the Role of the Immune System in HIV Persistence?co-chairs – alan landay, uS and nicolas chomont, uS

this session will focus on the immune mechanisms contribut-ing to hIV persistence in indi-viduals treated with haart. the main hIV reservoir is a small pool of latently infected cells that persist in successfully treated subjects. the immune mechanisms implicated in the establishment and maintenance of these latently infected cells are still poorly understood. a better understanding of these mechanisms would allow the design of new therapeutic strategies that may prevent the establishment of this stable viral reservoir and contribute to its depletion. although hIV eradication constitutes an ulti-mate goal, recent data suggest that a potent immune response should be able to control hIV reactivation from its reservoirs. In this regard, this session will also focus on the important role played by HIV-specific immune responses in the control of hIV reactivation under haart.

Overview Speakerbrigitte Autran, is head of the pitié-Salpêtrière Institute of research on Immunity-cancer and Infection. She has deve-loped key research on the immu-nology of the infection caused by hIV and cell-mediated immunity as well as memory to various anti-viral vaccines. She has dedicated her research to the comprehension of the immune defenses raised against hIV, with a major interest for the therapeutic and vac-cine applications of her work. She acts as a vaccine expert at the French ministry of health and is a member of the Who Global advisory committee on Vaccine Safety.


17 July 2010

13

Abstracts S3.1. Homeostatic prolifera-tion of memory T-cells and expansion of the HIV-1 latent reservoir, A. Bosque, V. Planelles, University of Utah, Pathology, Salt Lake City, United States, under embargo until 21 July 2010.

S3.2. Systemic immune acti-vation and duodenal CD4+ T-cell depletion are associated with increased proportions of gut Enterobacteriales and bacteroidales by 16S rDnA sequence analysis in HIV infected subjects, C.L. Ellis1, D.M. Asmuth1, S. Mann1,2, Z.-M. Ma3, C.-S. Li1, J. Wu1, T.H. Knight1, H. Overman4, A. Maniar1, R. Byun1,2, D. Defreitas1, X.-D. Li1, N. Torok1, A. Albanese2, J.A. Eisen5, J.C. Rutledge1, C.J. Miller1,3, R.B. Pollard1, 1University of California Davis Medical Center, Internal Medicine, Sacramento, United States, 2Mather Veterans Administration Hospital, Internal Medicine, Mather, United States, 3California National Primate Research Center, University of California, Davis, Davis, United States,

4University of California Davis, Davis, United States, 5University of California Davis, Medical Microbiology, Davis, United States, under embargo until 20 July 2010.

S3.3. Myeloid dendritic cells induce HIV-1 latency in non-proliferating CD4+ T-cells, V.A. Evans1, S. Saleh1, E.K. Haddad2,3, P.U. Cameron1,4, R.-P. Sekaly2,3, S.R. Lewin1,4,5, 1Monash University, Medicine, Victoria, Australia, 2CHUM-Research Center, Saint-Luc Hospital, Montreal, Canada, 3VGTI-Florida, Port St Lucie, United States, 4Alfred Hospital, Infectious Diseases Unit, Melbourne, Australia, 5Burnet Institute, Melbourne, Australia, under embargo until 20 July 2010.

S3.4. Protective HlA alleles limit HIV reservoir in long-term non-progressors central memory CD4+ T-cells, B. Descours1, V. Avettand Fenoel2, C. Blanc3, A. Samri1, A. Mélard2, V. Supervie4, G. Carcelain1, C. Rouzioux2, B. Autran1, ALT ANRS CO15,

1UPMC, Paris VI, umrs945, Paris, France, 2Université Paris Descartes, EA3620, Laboratoire de Virologie, Paris, France, 3UPMC, Paris VI, Plateforme de Cytométrie en Flux inter IFR, Paris, France, 4UPMC, Paris VI, umrs943, Paris, France, under embargo until 21July 2010.

S3.5. HIV-1 elite controllers resist HIV-1 infection via p21 (cip-1/waf-1), H. Chen1, T. Cung1, K. Seiss1, J. Beamon1, J. Huang1, P. Burke1, B. Ryan1, L. Porter1, R. Weiss2, A. Brass1, E. Rosenberg3, B. Walker1, X. Yu1, M. Lichterfeld3, 1Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Boston, United States, 2University of California at Davis, Davis, United States, 3Infectious Disease Division, Massachusetts General Hospital, Boston, United States, under embargo until 22 July 2010.

10:45-12:30 What Host Factors are at Play?co-chairs – Jacques Fellay and David Goldstein, uS

It has been well established that host genetic differences have a strong influence on patient dif-ferences in viral control. this session reviews what is known about the host genetic determi-nants of viral control and what future studies are needed to develop a more comprehensive view of the genetic contributions to control.

Overview SpeakerPaul de bakker is assistant professor of medicine in the Division of Genetics at the brigham and Women’s hospital and harvard medical School, and an associate member of the broad Institute of harvard and mIt. he is currently lea-ding the host genetics pro-jects of the International hIV controllers Study. his research focuses on the characterization of Dna sequence variation in human populations.

Abstracts S4.1. Tetherin restricts direct cell-cell viral transfer and transmission of HIV-1, B. Kuhl, R. Sloan, D. Donahue, T. Bar-Magen, C. Liang, M. Wainberg, McGill University AIDS Center, Montreal, Canada, under embargo until 21July 2010.

S4.2. The role of the ubiqui-tin-proteasome pathway in rhTRIM5 restriction of HIV-1, C. Danielson, T. Hope, Northwestern University, Cell and Molecular Biology, Chicago, United States, under embargo until 21 July 2010.

S4.3. lEDGF/p75 is critical but not essential for multiple round HIV-1 replication, R.L.G. Schrijvers1, J. De Rijck1, R. Gijsbers1, K. Ronen2, F.D. Bushman2, Z. Debyser1, 1KU Leuven, Molecular Virology and Gene Therapy, Leuven, Belgium, 2University of Pennsylvania, School of Medicine, Philadelphia, United States, under embargo until 20 July 2010.Paul de Bakker


14

S4.4. Changes in CD4+ cells miRnA expression following exposure to HIV-1, F. Bignami1, E. Pilotti2, L. Bertoncelli3, P. Ronzi1, M. Gulli4, N. Marmiroli4, G. Magnani5, M. Pinti3, C. Mussini6, L. Lopalco7, R. Ruotolo8, M. Galli1, A. Cossarizza3, C. Casoli1, 1Università degli Studi di Milano, Dipartimento di Scienze

15

Cliniche, Milano, Italy, 2ANLAIDS Lombardia, Milano, Italy, 3Università di Modena e Reggio Emilia, Dipartimento di Scienze Biomediche, Modena, Italy, 4Università degli Studi di Parma, Dipartimento di Scienze Ambientali, Parma, Italy, 5Arcispedale S. Maria Nuova, Unità Operattiva di Malattie Infettive, Reggio Emilia, Italy,

6Policlinico di Modena, Clinica delle Malattie Infettive, Modena, Italy, 7Fondazione Centro San Raffaele, Divisione di Immunologia, Malattie Infettive e Trapianti, Milano, Italy, 8Università degli Studi di Parma, Dipartimento di Biochimica e Biologia Molecolare, Parma, under embargo until 21July 2010.


14:30-16:15 What are Potential Therapeutic Interventions and How to Evaluate Them?co-chairs – christine katlama, France and alain lafeuillade, France

the aim of this session is to define what kind of therapeutic strategies must be developed to specifically target HIV res-ervoirs and sanctuaries, and what the needed tools to assess their effect are. an overview will be given of what is currently in progress in terms of therapeu-tic trials. the potential of new compounds to move into clini-cal trials, like anti-latency drugs, will be discussed. the best time in the natural history of hIV dis-ease to target reservoirs will also be addressed (i.e. acute or chronic infection). Finally, the session will review the viro-logic and pharmacologic tools currently available to assess therapeutic efficacy at the res-ervoir level. the limitations of these tests and the nature of the compartments to be tested will be discussed. this will help defining the primary end points of efficacy that could be used in therapeutic trials focusing on hIV reservoirs.

Overview SpeakerFrank Maldarelli is head of the In Vivo biology Group in the national cancer Institute’s hIV Drug resistance program, attending physician in the nIaID/ccmD hIV service, he is currently a faculty member of the International Society of Infectious Diseases hIV training program, nIh Infectious Disease consult Service, and center for bio-medical communications Infectious Disease board review course, and a lecturer in the Washington D.c. community outreach pact program.

16

17

Abstracts S5.1. Impact of raltegravir on immune reconstitution and thymopoiesis in HIV-1-infected patients with unde-tectable viremia on HAART, C. Garrido, N. Rallon, N. Zahonero, M. López, V. Soriano, C. de Mendoza, J.M. Benito, Hospital Carlos III, Infectious Diseases, Madrid, Spain, under embargo until 22 July 2010.

S5.2. Effect of 24-weeks intensificaction with a CCR5-antagonist on the decay of the HIV-1 latent reservoir, L. Díaz1, C. Gutierrez2, C. Page2, R. Lorente1, B. Hernández-Novoa2, A. Vallejo2, E. Domínguez2, M. Abad2, N. Madrid2, A. Moreno2, M.J. Pérez-Elías2, R. Rubio3, M.Á. Muñoz-Fernández1, S. Moreno2, 1Hosp General Universitario Gregorio Marañón, Madrid, Spain, 2Hospital Ramón y Cajal, Madrid, Spain, 3Hosp Universitario Doce de Octubre, Madrid, Spain, under embargo until 20 July 2010.

S5.3. Epigenetic drug Gar1041 in combination with antiretro-viral therapy (ART) transiently reduces the proviral DnA res-ervoir in SIVmac251-infected macaques, M. Lewis1, S. Norelli2, N. Chomont3, S. De Fonseca3, M. Sgarbanti2, M. Collins1, B. Chirullo2, J. Yalley Ogunro1, J. Greenhouse1, A.T. Palamara4, E. Garaci2, A. Savarino5, 1Bioqual, Rockville, United States, 2Istituto Superiore di Sanità, Rome, Italy, 3VGTI-Florida, Port St. Lucie, United States, 4Università La Sapienza, Rome, Italy, 5Istituto Superiore di Sanita, Dept. of Infectious, Parasitic and Immune Diseases, Rome, Italy, under embargo until 19 July 2010.

S5.4. Purging the HIV-1 reser-voir through the disruption of the PD-1 pathway S. Da Fonseca1, N. Chomont1, M. El-Far2,3,4, R. Boulassel5, J.-P. Routy6, R.-P. Sekaly1,2,3,4,1Vaccine and Gene Therapy Institute, Port St Lucie, United States, 2Laboratoire d’Immunologie, Centre de Recherche du Centre Hospitalier de l’Université de

Montréal (CR-CHUM) Saint Luc, Montréal, Canada, 3Laboratoire d’Immunologie, Département de Microbiologie et d’Immunologie, Université de Montréal, Montréal, Canada, 4INSERM U743, CR-CHUM, Université de Montréal, Montréal, Canada, 5Immunodeficiency Service and Division of Hematology, Royal Victoria Hospital, McGill University Health Centre (MUHC), McGill University, Montréal, Canada, 6Department of Microbiology and Immunology, McGill University, Montréal, Canada

S5.5. Measurements of total and integrated HIV DnA dem-onstrate sporadic blips of unintegrated HIV DnA in HIV+ patients on HAART, A. Mexas1, E. Graf1, L. Agosto1, J.J. Yu1, M. Pace1, M. Liszewski1, S. Migueles2, M. Connors2, U. O’Doherty1, 1Uninversity of Pennsylvania, Pathology and Laboratory Medicine, Philadelphia, United States, 2NIAID, NIH, Bethesda, United States. under embargo until 19 July 2010.


Sharon Lewin

16:45-17:45 Closing Session co-chairs – christine rouzioux, France and paula munderi, uganda

the closing session will look at eradication prospects. Sharon lewin, who will be presenting at aIDS 2010 a plenary on “Strategies for a cure”, will share the highlights of her presenta-tion. She will discuss strategies for moving some of the findings from basic science into the clini-cal field, comment on the design of clinical trials to evaluate eradi-cation or long term suppression, and raise some human rights issues linked to these questions. In the keynote address Daria hazuda will focus on the crucial line which crosses the field of hIV basic science: is there hope for eradication of hIV in infec-ted individuals possible or is long-term remission of infected individuals the only realistic goal researchers can pursue.

HIV Reservoirs at AIDS 2010Speaker Sharon lewin is Director of the Infectious Diseases unit at the alfred hospital; professor of medicine at monash university in melbourne; and co-Director of the centre for Virology, burnet Institute, melbourne, australia lewin heads a research labora-tory that aims to understand why hIV and hepatitis b virus persist and evade the immune system. lewin is the immediate past president of the australasian Society for hIV medicine. She will give a plenary presentation at the opening Session of aIDS 2010 about the State of the Epidemic: Strategies for a Cure.

Eradication versus Remission: Is Eradication possible?Keynote Speaker Daria Hazuda, is the Worldwide head of antiviral and Infectious Disease basic research at merck research labs. She joined the antiviral research group at merck in 1989. Daria has more than one hundred-fifty publications focused primarily on antiviral research in the fields of hIV and hcV. previously; she was the Global Director of Scientific Affairs for Antivirals at merck in the division of Global human health and was respon-sible for establishing the post marketing scientific leadership strategy for Isentress. Daria Hazuda

18

19

Theme 1 - Where and what are viral reservoirs?1. Assessment of residual HIV-1 viremia and persistent viral replication in highly sup-pressed patients: comparison of direct and indirect methods, B. Hernandez-Novoa1, N. Madrid1, A. Vallejo1, C. Gutierrez1, L. Diaz2, M. Abad1, E. Dominguez1, V. Dahl3, R. Rubio4, E. Navas1, J. Zamora1, H. Valdez5, S. Palmer3, M.A. Muñoz-Fernandez2, S. Moreno1, 1Hospital Ramon y Cajal, Madrid, Spain, 2Hosp General Universitario Gregorio Marañón, Madrid, Spain, 3Swedish Institute Of Infectious Diseases Control and Karolinska Institute, Stockholm, Sweden, 4Hospital Doce de Octubre, Madrid, Spain, 5Pfizer Inc., New York, United States. under embargo until 21 July 2010.

2. Impact of short term HAART on SIV infection of the male genital tract, M. Moreau1, A. Le Tortorec1, H. Denis1, C. Deleage1, A.-P. Satie1, O. Bourry2, P. Roques2, B. Jégou1, R. Le Grand2, N. Dejucq-Rainsford1,

1INSERM U625, Rennes, France, 2Immunovirology, CEA, Fontenay-aux-Roses, France, under embargo until 21 July 2010.

3. Effect of a CCR5 antago-nist in immune activation in highly suppressed HIV-1 infected patients, A. Vallejo1, L. Diaz2, M. Abad1, C. Gutiérrez1, B. Hernández1, E. Domínguez1, N. Madrid1, F. Dronda1, J.L. Casado1, R. Rubio3, E. Muñoz4, M.Á. Muñoz-Fernández2, S. Moreno1, 1Hospital Ramón y Cajal, Enfermedades Infecciosas, Madrid, Spain, 2Hospital Gregorio Marañon, Laboratorio Inmunobiología Molecular, Madrid, Spain, 3Hospital 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain, 4Universidad de Cordoba, Cordoba, Spain. under embargo until 20 July 2010.

4. Role of the viral reservoir on adaptive HIV-1 evolution throughout viral recombina-tion under ART and immune pressures, M.J. Buzon1, T. Wrin2, F.M. Codoñer1, J. Dalmau1, A. Bonjoch3, E. Coakley2, B. Clotet4, J. Martinez-Picado5, 1Irsicaixa AIDS Research Institute, Badalona, Spain, 2Monogram Biosciences, South San Francisco, United States,

3Lluita contra la SIDA Foundation, Germans Trias University Hospital, Badalona, Spain, 4Irsicaixa AIDS Research Institute, LLuita contra la SIDA Foundation, Badalona, Spain, 5Irsicaixa AIDS Research Institute, Institució Catalana de Reserca i Estudis Avançats (ICREA), Badalona, Spain. under embargo until 22 July 2010.

5. Rapid infectious viral assay (RIVA) of monocytes in patients with Vl< 50 copies/ml of blood,O.A. Ducoudret, N.S. Baichoo, M.R. Ruff, C.B. Pert, L. Agrawal, RAPID Laboratories, Rockville, United States. under embargo until 20 July 2010.

6. The prevalence of CXCR4-using HIV-1 subtype C variants during progressive infection is comparable to subtype b infection, but is not associated with accelerated CD4+ T-cell decline,M.R. Jakobsen1,2, A. Ellett1, C. Erikstrup2,3, L. Gray1,4, H. Hoare1, N. Saksena5, B. Wang5, D. Purcell6, H. Ullum3, P. Kallestrup3, R. Zinyama-Gutsire7, E. Gomo7, L. Østergaard2, M. Churchill1,4, P. Gorry1,4,6, 1Burnet Institute, Centre of Virology, Melbourne, Australia,

Poster Exhibition the poster exhibition is divided in thematic sessions corresponding to the workshop’s session’s themes.

Poster Exhibition (Continued)2Aarhus University Hospital, Skejby, Department of Infectious Diseases, Aarhus, Denmark, 3Rigshospitalet, Department of Clinical Immunology, Copenhagen, Denmark, 4Monash University, Department of Medicine, Melbourne, Australia, 5Westmead Millennium Institute, Sydney, Australia, 6University of Melbourne, Department of Microbiology and Immunology, Melbourne, Australia, 7National Institute of Health Research, Harare, Zimbabwe. under embargo until 20 July 2010.

7. naïve CD4+ T-cell are latent-ly infected in vitro and in vivo, A. Mexas1, L. Agosto1, M. Liszewski2, M. Pace2, S. Migueles3, J. Brenchley3, M. Connors3, U. O’Doherty1, 1University of Pennsylvania, Pathology and Laboratory Medicine, Philadelphia, United States, 2University of Pennsylvania, Philadelphia, United States, 3NIAID, Bethesda, United States. under embargo until 20 July 2010.

8. The chemokine receptors CCR4 and CXCR3 are biomar-kers for central memory CD4+ T-cell subsets with increased

permissiveness to HIV-1 inte-gration in infected individuals, A. Gosselin1,2, P. Monteiro1,2,3, N. Chomont1,2,4, M. El-Far1,2, M.-R. Boulassel5, J.-P. Routy3,5, R.-P. Sekaly1,2,3,4, P. Ancuta1,2,3, 1Universite de Montreal, Microbiologie et Immunologie, Montreal, Canada, 2CHUM-Research Center, Saint-Luc Hospital, Montreal, Canada, 3The French National Institute of Health and Medical research Unit 743, Montreal, Canada, 4Vaccine and Gene Therapy Institute, Port Saint Lucie, United States, 5Mc Gill University Health Centre, Montreal, Canada under embargo until 22 July 2010.

Theme 2 - What are the mechanisms of persistence?9. Promoter-targeted siRnA colocalizes with Argonaute 1 and 2 during RnA-induced transcriptional gene silencing of simian immunodeficiency virus infection,C.L. Hood1,2, H.G. Lim1,2, K. Suzuki1, D.A. Cooper1,2, A.D. Kelleher1,2, 1St. Vincent’s Centre for Applied Medical Research, Immunovirology Laboratory, Darlinghurst, Australia, 2National Center in HIV Epidemiology and Clinical Research, Darlinghurst, Australia, under embargo until 20 July 2010.


20

21

10. Human microRnA and the regulation of HIV-1 expression/replication, L. Houzet, K.T. Jeang, NIH, Bethesda, United States. under embargo until 20 July 2010.

11. Rrp6 represses transcrip-tion from the HIV-1 promoter, X. Contreras, E. Rousset, R. Kiernan, IGH, CNRS, Montpellier, France. under embargo until 21 July 2010.

12. SJ23b, a jatrophane diter-pene, induces HIV Receptors down-regulation and HIV transcription through activa-tion of PKCs and Ras-MEK pathway, L.M. Bedoya1, N. Marquez2, N. Martinez3, S. Gutiérrez-Eisman3, A. Alvarez1, M.A. Calzado2, J.M. Rojas3, G. Appendino4, E. Muñoz2, J. Alcami1, 1Centro Nacional de Microbiología, Instituto de Salud Carlos III, AIDS Immunopathology Department, Majadahonda, Spain, 2Facultad de Medicina, Universidad de Córdoba, Departamento de Biología Celular, Fisiología e Inmunología, Cordoba, Spain, 3Centro Nacional de Microbiología, Instituto de Salud Carlos III, Cellular Biology Department, Majadahonda, Spain,

4Università del Piemonte Orientale, Dipartimento di Scienze Chimiche, Alimentari, Farmaceutiche e Farmacologiche, Novara, Italy. under embargo until 20 July 2010.

13. Post-transcriptional blocks limit HIV-1 expression in a novel in vitro model of HIV latency in primary T-cells,S. Saleh1, P. Cameron1,2, V. Evans1, G. Sallmann1, A. Solomon1, F. Wightman1, E. Haddad3,4, R.-P. Sekaly3,4, S. Lewin1,2,5, 1Monash University, Medicine, Melbourne, Australia, 2Infectious Diseases Unit, Alfred Hospital, Melbourne, Australia, 3University of Montreal, Montreal, Canada, 4VGTI, Florida, United States, 5Burnet Institute, Melbourne, Australia. under embargo until 20 July 2010.

14. HIV uses cellular miRnA to overcome cell restriction factors and to better replicate, C. Chable-Bessia1, O. Meziane1, S. Emiliani2, O. Schwartz3, O. Lambotte4, Y. Lévy5, B. Autran6, J. Reynes7, Y. Bennasser1, M. Benkirane1, 1Institute of Human Genetic, CNRS, Laboratory of Molecular Virology, Montpellier, France, 2Cochin Institute, CNRS, Interaction Host-Virus, Paris, France, 3Pasteur Institute, Virus and Immunity Unit, Paris, France, 4Kremlin Bicêtre Hospital, Paris, France,

5INSERM U955, Université Paris 12, Immunologie Clinique, Créteil, France, 6Pitié-Salpétrière Hospital, INSERM U945, Cellular Immunology Laboratory, Paris, France, 7CHU Montpellier, Infectious Diseases Department, Montpellier, France. under embargo until 20 July 2010.

15. A three years follow-up of long term control of HIV-1 after allogeneic CCR5-delta32 stem cell transplantation, K. Allers1, T. Schneider1, C. Loddenkemper2, J. Hofmann3, K. Rieger4, E. Thiel4, G. Hütter5, 1Charité Universitätsmedizin Med I, Berlin, Germany, 2Charité Universitätsmedizin Institut für Pathologie, Berlin, Germany, 3Charité Universitätsmedizin Institut für Virologie, Berlin, Germany, 4Charité Universitätsmedizin Med III, Berlin, Germany, 5Institut für Transfusionsmedizin und Immunologie, Mannheim, Germany. under embargo until 20 July 2010.

16. Influence of chromatin at the integration site on the establishment of HIV latency: a role for co-transcriptional chromatin reassembly factors, E. Gallastegui, A. Jordan, Institut de Biologia Molecular de Barcelona-CSIC, Molecular Genomics, Barcelona, Spain.

Poster Exhibition (Continued)17. HIV eradication and the development of drug resis-tance in humanized mice, P. Denton, S. Choudhary, D. Margolis, J.V. Garcia, University of North Carolina at Chapel Hill, Medicine - Infectious Diseases, Chapel Hill, United States.

18. Identification of Tat-responsive pre-initiation com-plexes (PICHs) at the HIV-1 core promoter, E. Wilhelm1, M.-C. Doyle2, N. Dumais2, B. Bell1, 1Université de Sherbrooke, Microbiologie et Infectiologie, Sherbrooke, Canada, 2Université de Sherbrooke, Biologie, Sherbrooke, Canada. under embargo until 19 July 2010.

19. The interplay between RnA splicing, chromatin, Tat and transcription from the HIV lTR: implications for HIV-1 post-integration latency, M.R. Alexander1, A.K. Wheatley1, R.J. Center1, K. Suzuki2, S. Saleh3, S.R. Lewin3,4, A. Kelleher2, D.F.J. Purcell1 1University of Melbourne, Microbiology and Immunology, Parkville, Australia, 2University of New South Wales, National Centre for HIV Epidemiology and Clinical Research, Sydney, Australia, 3Monash University, Department of Medicine, Melbourne, Australia,

4Alfred Hospital, Infectious Diseases Unit, Melbourne, Australia. under embargo until 19 July 2010.

What is the role of the immune system in HIV persistence?20. Unique functional proper-ties of dendritic cells in HIV-1 elite controllers, J. Huang1, P. Burke1, F. Peyrera1, B. Walker1, L. Borges2, M. Lichterfeld3, X.G. Yu1, 1Ragon Institute of Massachusetts General Hospital, MIT and Harvard, Charlestown, United States, 2Amgen Inc., Seattle, United States, 3Infectious Disease Division, Massachusetts General Hospital, Boston, United States, under embargo until 20 July 2010.

21. Rebound with original virus after sustained HIV suppression on antiretroviral therapy (ART) and daily ultra-low dose interleukin-2 (Il-2) suggests Il-2 enhancement of anti-HIV immunity, J. Margolick1, M. James2, L. Apuzzo1, S. Langan1, J. Gallant3, S. Eshleman2, 1Johns Hopkins Bloomberg School of Public Health, Molecular Microbiology and Immunology, Baltimore, United States, 2Johns Hopkins University School of Medicine, Pathology, Baltimore, United States,


22

23

3John Hopkins University School of Medicine, Medicine, Baltimore, United States. under embargo until 22 July 2010.

22. Increased thymic pro-duction of naive regulatory T-cells distinguish patients with HAART-mediated control from those with spontaneous control of HIV, N.I. Rallón, C. Restrepo, M. Salgado, C. de Mendoza, S. Lozano, M. López, A. Peris, V. Soriano, J.M. Benito, Infectious Diseases Department. Hospital Carlos III, Madrid, Spain. under embargo until 21 July 2010.

23. Role of nFAT in reactiva-tion of HIV-1 latency in prima-ry memory CD4+ T-cells,A. Bosque, V. Planelles, University of Utah, Pathology, Salt Lake City, United States

24. Peripheral blood CCR4+ CCR6+ and CXCR3+ CCR6+ CD4+ T-cells are highly per-missive to HIV-1 infection, P. Monteiro1,2,3, A. Gosselin1,2, N. Chomont1,2, F. Diaz-Griffero4, E.A. Said1,2, S. Fonseca1,2, V. Wacleche1,2,3, M. El-Far1,2, M.-R. Boulassel5, J.-P. Routy3,5, R.-P. Sekaly1,2,3, P. Ancuta1,2,3, 1Université de Montréal, Microbiologie et Immunologie, Montreal, Canada, 2CHUM-Research Center, Saint-Luc Hospital, Montreal, Canada, 3The French National Institute of Health and Medical research Unit 743, Montreal, Canada,

4Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States, 5McGill University Health Center, Montreal, Canada. under embargo until 21 July 2010.

25. low levels of immune acti-vation in viremic non-progres-sors HIV-infected individuals, J. Taaffe1, B. Julg2, B. Rodriguez3, S. Gordon4, I. Frank1, D. Ripamonti5, A. Gori6, M. Lederman3, B. Walker2, C. Torti7, G. Silvestri1,8, 1University of Pennsylvania, Philadelphia, United States, 2Ragon Institute of MGH, MIT, and Harvard, Boston, United States, 3Case Western Reserve University, Cleveland, United States, 4National Cancer Insititute, Frederick, United States, 5Ospedali Riuniti, Bergamo, Italy, 6San Gerardo Hospital, Monza, Italy, 7University of Brescia, Brescia, Italy, 8Yerkes National Primate Research Center, Atlanta, United States, under embargo until 19 July 2010.

26. Impact of antigen persis-tence on CD4+ T-cell activa-tion in chronic HIV infection, M.Z.D. Smith1, U. Karrer2, S. Bastidas1, A. Oxenius1, 1ETH Zurich, Institute for Microbiology, Zurich, Switzerland, 2The University Hospital of Zurich, Division of Infectious Diseases and Hospital Epidemiology, Zurich, Switzerland.

What host factors are at play?27. APObEC3G genetic variants do not influence CD4 T-cell counts, HIV viral load and are not associa-ted with protection against HIV-1 infection, J.A. Vázquez Perez, G. Cerezo, C.E. Ormsby, R. Hernandez-Juan, K.J. Torres, G. Reyes-Teran, Instituto Nacional de Enfermedades Respiratorias, Centro de Investigación en Enfermedades Respiratorias, Mexico. under embargo until 20 July 2010.

28. Il-10 promoter genetic variants affect Il-10 plasma levels, breadth of cytotoxic T-cell lymphocte response and the rate of CD4 T-cell loss during chronic HIV-1 infection, D.D. Naicker1, B. Wang2, E. Losina2, J. Zupkosky3, T. Hongo3, S. Reddy4, K. Bishop4, F. Chonco4, P.J.R. Goulder3,4,5, B.D. Walker3,4,6, D.E. Kaufmann3,7, T. Ndung’u3,4, 1University of KwaZulu-Natal, Hasso Plattner Research Program, Durban, South Africa, 2Program in HIV Outcomes Research, Massachusetts General Hospital, Boston, United States, 3Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Boston, United States,

Poster Exhibition (Continued)4HIV Pathogenesis Programme, Doris Duke Medical Research Institute, University of KwaZulu- Natal, Durban, South Africa, 5Department of Paediatrics, Nuffield Department of Medicine, Oxford, United Kingdom, 6Howard Hughes Medical Institute, Chevy Chase, United States, 7Harvard Medical School, Boston, United States. under embargo until 21 July 2010.

29. Detection of HIV-1 proviral hypermutation and evalua-tion of its association with disease outcomes, V. Correa Vieira1, A. de Oliveira Afonso2, J. Silveira1, E. Stankiewicz Machado2,3, M. Alves Soares2, A.M. Barral de Martinez1, 1Universidade Federal do Rio Grande, Rio Grande, Brazil, 2Universidade Federal do Rio de Janeiro, Departamento de Genética, Rio de Janeiro, Brazil, 3Universidade Federal do Rio de Janeiro, Hospital Universitário Clementino Fraga Filho, Rio de Janeiro, Brazil. under embargo until 20 July 2010.

30. Polymorphisms in the lens epithelium derived growth factor/p75 gene (PSIP1) influence suscepti-bility to HIV-1 infection and disease progression, P. Madlala1,2, A. Hombrouck3, R. Gijsbers4, F. Christ3, L. Werner5, E. Kormuth6,

K. Mlisana7, S.A. Karim7, C. Winkler8, Z. Debyser4, T. Ndung’u1,5, the CAPRISA Acute Infection Study Team, 1University of KwaZulu-Natal, HIV Pathogenesis Programme, Durban, South Africa, 2University of KwaZulu-Natal, Genetics Department, Pietermaritzburg, South Africa, 3Katholieke Universiteit Leuven, Molecular Medicine, Leuven, Belgium, 4Katholieke Universiteit Leuven, Molecular Medicine, B- Leuven, Belgium, 5University of KwaZulu-Natal, Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa, 6University of KwaZulu-Natal, Genetics Department, Pietermaritzburg, South Africa, 7University of KwaZulu-Natal, Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa, 8National Cancer Institute-Frederick, Laboratory of Genomic Diversity, Frederick, United States. under embargo until 20 July 2010.

31. Single nucleotide poly-morphisms (SnPs) in cyto-kine-coding genes in HIV-infected patients from brazil, A.R.O. Léda1, A.N. Barbosa2, R.A.M.B. Almeida2, L.R. Souza2, D.A. Meira2, D. Elgui de Oliveira1, 1Sao Paulo State University, Department of Pathology, Botucatu, Brazil,


24

25

2Sao Paulo State University, Department of Tropical Diseases and Image Diagnosis, Botucatu, Brazil, under embargo until 20 July 2010.

32. Emetine blocks RnA pro-cessing bodies and impacts on HIV replication, A.L.C. Valadão1, B.M. Peterlin2, A. Tanuri1, R.S. Aguiar1, 1Universidade Federal do Rio de Janeiro, Genética, Rio de Janeiro, Brazil, 2University of California San Francisco, San Francisco, United States. under embargo until 20 July 2010.

33. HIV-1 Vpu and TASK proteins inhibit HIV-1 transcription,N. Emeagwali, J. Hildreth Meharry Medical College, Center For AIDS Health Disparities Research, Nashville, United States.

What are potential therapeutic interventions and how to evaluate them?34. Persistent low-level vire-mia despite clinically suc-cessful antiretroviral therapy appears to be correlated with more frequent resting CD4+ T-cell infection, N. Archin1, J. Anderson1, K. Keedy1, K. Barton1, M. Cheema1, R. Sackmann1, A. Wiegand2, J. Kuruc1, J. Eron1, M. Cohen1, J. Coffin2,

R. Swanstrom1, D. Margolis1, 1The University of North Carolina, Medicine, Chapel Hill, United States, 2NCI HIV Drug Resistance Program, Frederick, United States. under embargo until 21 July 2010.

35. level of HIV-1 unspliced RnA in peripheral blood mononuclear cells: a longi-tudinal marker of infection progression in untreated individuals and a predictive marker of virological rebound in patients on antiretroviral therapy with undetectable plasma viremia, A. Pasternak1, S. Jurriaans1, M. Bakker1, J. Prins2, B. Berkhout1, V. Lukashov1, 1Academic Medical Center of the University of Amsterdam, Medical Microbiology, Amsterdam, Netherlands, 2Academic Medical Center of the University of Amsterdam, Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, Amsterdam, Netherlands, under embargo until 22 July 2010.

36. Susceptibility of human seminal vesicles to HIV-1 infection, C. Deléage1, H. Denis1, N. Rioux-Leclercq2, A. Ruffault3, B. Jégou1, N. Dejucq-Rainsford1, 1INSERM U625, Rennes, France, 2Anathomo-pathology, Rennes University Hospital, Rennes, France,

3Retrovirology, Rennes University Hospital, Rennes, France. under embargo until 20 July 2010.

37. Association between geni-tal tract inflammation during acute HIV-1 infection and HIV disease progression, L. Roberts1, J.-A. Passmore1,2, C. Williamson1,3, F. Little1, L. Bebell3,4, K. Mlisana3, F. van Loggerenberg3, G. Walzl5, Q. Abdool Karim3,4, S. Abdool Karim3,4,1University of Cape Town, Cape Town, South Africa, 2National Health Laboratory Services, Cape Town, South Africa, 3Centre for AIDS Programme of Research (CAPRISA), Durban, South Africa, 4Columbia University, New York, United States, 5University of Stellenbosch, Cape Town, South Africa. under embargo until 23 July 2010.

38. The cell-associated HIV-1 DnA level after 15 years of perinatal infection is strongly correlated with lifetime viral replication - The AnRS-EP38-IMMIP Study, V. Avettand-Fenoel1, S. Blanche1, J. Lechenadec2, C. Dollfus3, D. Scott-Algara4, J.-P. Viard1, N. Bouallag2, Y. Benmebarek2, Y. Rivière5, J. Warszawski2,6, C. Rouzioux1, F. Buseyne5, 1Université Paris Descartes, EA3620, Hôpital Necker-Enfants malades, AP-HP, Paris, France,

Poster Exhibition (Continued)2CESP INSERM U1018, Le Kremlin-Bicêtre, France, 3Hôpital Trousseau, Paris, France, 4Institut Pasteur, Unité de Régulation des Infections Rétrovirales, Paris, France, 5Institut Pasteur, Laboratoire d’Immunopathologie virale, Paris, France, 6Université Paris-Sud, Le Kremlin-Bicêtre, France. under embargo until 19 July 2010.

39. Immunotoxin complemen-tation of HAART to deplete persisting HIV infected cell reservoirs, E. Berger1, I. Pastan2, 1National Institutes of Health, Laboratory of Viral Diseases, NIAID, Bethesda, United States, 2National Institute of Health, Laboratory of Molecular Biology, NCI, Bethesda, United States, under embargo until 20 July 2010.

40. Synergistic activation of HIV-1 expression by deacety-lase inhibitors and prostratin: implications for treatment of latent infection, S. Reuse1, L. Colin1, M. Calao1, K. Kabeya2, J.-S. Gatot1, S. Bouchat1, A. Guiguen1, V. Quivy1, C. Vanhulle1, C. Cardona1, A. Lamine3, D. Vaira4, D. Demonte1, V. Martinelli1, E. Veithen1, T. Cherrier5, V. Avettand6, S. Poutrel3, J. Piette7,

Y. de Launoit8, M. Moutschen4, A. Burny1, C. Rouzioux6, S. De Wit2, G. Herbein9, O. Rohr5, Y. Collette10, O. Lambotte3, N. Clumeck2, C. Van Lint1, 1Laboratory of Molecular Virology, Institut de Biologie et de Médecine Moléculaires (IBMM), Université Libre de Bruxelles (ULB), Gosselies, Belgium, 2Service des Maladies Infectieuses, CHU St-Pierre, ULB, Brussels, Belgium, 3INSERM U802, Bicêtre, France, 4AIDS Reference Center, University of Liege (ULg), Liege, Belgium, 5INSERM U575, Virology Institute, Strasbourg, France, 6Laboratory of Virology, AP-HP, CHU Necker-Enfants Malades, Paris, France, 7Laboratory of Virology and Immunology, GIGA-R, University of Liege (ULg), Liege, Belgium, 8Institut de Biologie de Lille, Institut Pasteur de Lille, Université de Lille 1, UMR8117 CNRS, BP447, Lille, France, 9Department of Virology, University of Franche-Comte, CHU de Besançon, EA3186 INSERM IFR 133, Besançon, France, 10INSERM U119, Marseille, France. under embargo until 20 July 2010.

41. amfAR research consor-tium on HIV eradication, R. Johnston, amfAR, The Foundation for AIDS Research, Research, New York, United States.


26

27

HIV Reservoirs Roadmap at AIDS 2010- Plenary Presentations

State of the epidemic: towards a cure, Sharon lewin

new concepts in hIV/aIDS pathogenesis: Implications for Interventions, anthony Fauci

- Symposia Sessions

Innate Immunity - key to control?

pathogenesis - the battle of the Immune System

- Oral Abstract Sessions

novel therapeutic Strategies

correlates of Immune protection

t-cell responses in hIV Infection

host restriction and Innate Immunity to hIV Infection

Immune activation and Inflammation

persistence of hIV reservoirs

- Poster Discussions

role of Dendritic cells in hIV Infection

Viral persistency and latency

molecular mechanisms of Drug resistance

- Professional Development Workshop

hIV reservoirs: what are the strategies for hIV eradication?

- Press Conference

towards a cure: hIV reservoirs and Strategies to control them

International AIDS Society - Workshop · International AIDS Society - Workshop ... line u2. 8...

Documents

Transcript of International AIDS Society - Workshop · International AIDS Society - Workshop ... line u2. 8...